Concepedia

Author

Vincenzo Famiglietti

University of Campania "Luigi Vanvitelli"ORCID

Also Known As

Famiglietti, Vincenzo, Lucia Esposito, V. Famiglietti, Vincenzo Famiglietti

73

Publications

894

Citations

16

H-Index

40

Concepts

All Affiliations

University of Campania "Luigi Vanvitelli"Casa Sollievo della SofferenzaIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Istituti di Ricovero e Cura a Carattere ScientificoFondazione IRCCS Istituto Nazionale dei Tumori
VF

About

Vincenzo Famiglietti is an author at University of Campania "Luigi Vanvitelli" specializing in medicine, oncology, and colorectal cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

7

7

234

2

Health Sciences

2

2

101

3

Immunology

2

2

86

4

Cell Biology

1

1

11

5

Microbiology

1

1

61

Vincenzo Famiglietti

×

25

Publications

791

Citations

15

H-Index

YearCitations

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With <i>RAS</i> Wild-type Metastatic Colorectal Cancer

Erika Martinelli, Giulia Martini, Vincenzo Famiglietti,

JAMA Oncology

2021

174

Clinical Practice Use of Liquid Biopsy to Identify RAS/BRAF Mutations in Patients with Metastatic Colorectal Cancer (mCRC): A Single Institution Experience

Pietro Paolo Vitiello, Vincenzo De Falco, Emilio Francesco Giunta,

Cancers

2019

65

Gut microbiota correlates with antitumor activity in patients with <scp>mCRC</scp> and <scp>NSCLC</scp> treated with cetuximab plus avelumab

Giulia Martini, Davide Ciardiello, Marcello Dallio,

International Journal of Cancer

2022

61

Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

Stefania Napolitano, Vincenzo De Falco, Giulia Martini,

JAMA Oncology

2023

53

Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer

Morena Fasano, Carminia Maria Della Corte, Raimondo Di Liello,

ESMO Open

2020

46

Anti-EGFR Rechallenge in Patients With Refractory ctDNA <i>RAS/BRAF</i> wt Metastatic Colorectal Cancer

Davide Ciardiello, Erika Martinelli, Teresa Troiani,

JAMA Network Open

2024

37

Panitumumab plus trifluridine/tipiracil as anti‐<scp>EGFR</scp> rechallenge therapy in patients with refractory <scp><i>RAS</i></scp> wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase <scp>II VELO</scp> trial

Stefania Napolitano, Davide Ciardiello, Vincenzo De Falco,

International Journal of Cancer

2023

36

HER2-Low Status Does Not Affect Survival Outcomes of Patients with Metastatic Breast Cancer (MBC) Undergoing First-Line Treatment with Endocrine Therapy plus Palbociclib: Results of a Multicenter, Retrospective Cohort Study

Francesca Carlino, Anna Diana, Anna Ventriglia,

Cancers

2022

32

Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience

Vincenza Caputo, Vincenzo De Falco, Anna Ventriglia,

Therapeutic Advances in Medical Oncology

2022

29

Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival

Davide Ciardiello, Vincenzo Famiglietti, Stefania Napolitano,

Clinical Colorectal Cancer

2022

25

Page 1